Eggermont AM - Search Results

1

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U; American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951. Schmidt H, et al. Among authors: eggermont am. J Clin Oncol. 2007 Apr 20;25(12):1562-9. doi: 10.1200/JCO.2006.09.0274. J Clin Oncol. 2007. PMID: 17443000 Clinical Trial.

2

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW, Oosterom R, Oskam R, Bolhuis RL, Stoter G. Goey SH, et al. Among authors: eggermont am. Br J Cancer. 1995 Nov;72(5):1283-8. doi: 10.1038/bjc.1995.501. Br J Cancer. 1995. PMID: 7577483 Free PMC article. Clinical Trial.

3

A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities.

Klaase JM, Kroon BB, Eggermont AM, van Geel AN, Schraffordt Koops H, Oldhoff J, Liénard D, Lejeune FJ, Berkel R, Franklin HR, et al. Klaase JM, et al. Among authors: eggermont am. Eur J Cancer. 1995;31A(1):58-63. doi: 10.1016/0959-8049(94)00372-c. Eur J Cancer. 1995. PMID: 7695980

4

Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma.

Lejeune F, Liénard D, Eggermont A, Schraffordt Koops H, Kroon B, Gérain J, Rosenkaimer F, Schmitz P. Lejeune F, et al. Circ Shock. 1994 Aug;43(4):191-7. Circ Shock. 1994. PMID: 7895325 Review.

5

Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.

Liénard D, Eggermont AM, Schraffordt Koops H, Kroon BB, Rosenkaimer F, Autier P, Lejeune FJ. Liénard D, et al. Among authors: eggermont am. Melanoma Res. 1994 Mar;4 Suppl 1:21-6. Melanoma Res. 1994. PMID: 8038591 Clinical Trial.

6

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.

Kruit WH, Bolhuis RL, Goey SH, Jansen RL, Eggermont AM, Batchelor D, Schmitz PI, Stoter G. Kruit WH, et al. Among authors: eggermont am. J Clin Oncol. 1993 May;11(5):921-4. doi: 10.1200/JCO.1993.11.5.921. J Clin Oncol. 1993. PMID: 8487055

7

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

Kruit WH, Punt CJ, Goey SH, de Mulder PH, Gratama JW, Eggermont AM, Bolhuis RL, Stoter G. Kruit WH, et al. Among authors: eggermont am. Br J Cancer. 1996 Sep;74(6):951-5. doi: 10.1038/bjc.1996.463. Br J Cancer. 1996. PMID: 8826864 Free PMC article.

8

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.

Eggermont AM, Schraffordt Koops H, Liénard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ. Eggermont AM, et al. J Clin Oncol. 1996 Oct;14(10):2653-65. doi: 10.1200/JCO.1996.14.10.2653. J Clin Oncol. 1996. PMID: 8874324

9

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Liénard D, Enk A, Dummer R, Hantich B, Geueke AM, Eggermont AM. Keilholz U, et al. Among authors: eggermont am. J Clin Oncol. 1997 Jul;15(7):2579-88. doi: 10.1200/JCO.1997.15.7.2579. J Clin Oncol. 1997. PMID: 9215828 Free article. Clinical Trial.

10

High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.

Kruit WH, Goey SH, Lamers CH, Gratama JW, Visser B, Schmitz PI, Eggermont AM, Bolhuis RL, Stoter G. Kruit WH, et al. Among authors: eggermont am. J Immunother. 1997 Jul;20(4):312-20. doi: 10.1097/00002371-199707000-00008. J Immunother. 1997. PMID: 9220321 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

664 results

Search Page

Filters